Efficacy and tolerance of Liraglutide for weight loss in obese type 2 diabetic hemodialysis patients - LIRADIA

Groupe Hospitalier Paris Saint-Joseph0 个研究点目标入组 30 人开始时间: 2020年1月20日最近更新: 2020年6月8日

试验速览

暂无简介。

•- Patient aged = 18 and <70
•- Patient on hemodialysis for more than 6 months
•- Type 2 diabetic patient
•- Patient with a BMI> 30 kg / m2 with a Temporary Contraindication for kidney transplant for renal transplant due to overweight by his graft center
•- Patient affiliated to a health insurance plan
•- French speaking patient
•- Patient having given free, informed and written consent
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range 10
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range 20

•- Patient with a Temporary Contraindication for kidney transplant for a cause other than overweight
•- Patient with personal or family history of thyroid medullary cancer
•- Patient with a history of acute or chronic pancreatitis
•- Patient who has already had hypersensitivity to liraglutide (or to any other component of the product)
•- Patient who has already had a severe digestive intolerance to taking GLP-1 receptor agonists (such as exenatide or lixisenatide)
•- Patient already included in an interventional risk research protocol (RIPH1)
•- Pregnant or lactating woman
•- Patient under guardianship or curatorship
•- Patient deprived of liberty

发起方